Scilex Holding Launches Co-Pay Programs For ZTlido And ELYXYB For Commercially Insured Patients And Addition Of ELYXYB To Multi-State Medicaid Pharmaceutical Purchasing Group To Purchasing Pool
Portfolio Pulse from Benzinga Newsdesk
Scilex Holding has introduced Co-Pay programs for ZTlido and ELYXYB, aimed at commercially insured patients. Additionally, ELYXYB has been added to the Multi-State Medicaid Pharmaceutical Purchasing Group's purchasing pool.
April 09, 2024 | 1:10 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Scilex Holding's launch of Co-Pay programs for ZTlido and ELYXYB and the addition of ELYXYB to the Medicaid purchasing pool could enhance the company's market penetration and revenue.
The introduction of Co-Pay programs for ZTlido and ELYXYB is likely to make these drugs more accessible to a broader range of patients, potentially increasing sales. The addition of ELYXYB to the Medicaid purchasing pool further expands its market reach, likely positively impacting Scilex Holding's revenue in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100